SGLT2i compared to other non-insulin antidiabetics in Primary Care patients with earlier diabetes. Cohort profile and sample characteristics of DIAB-CV-AP study
Abstract
AIM
To describe the methodology and baseline characteristics of the sample of the DIAB-CV-AP study which, as a general objective of the cohort, aims to analyse the possible protective effect of iSGLT2 associated with metformin in patients with T2DM.
METHODS
The National Health System's BIFAP Primary Care prescription database was used, which includes information on 20,831,855 patients. A total of 52,739 patients were identified who started a second non-insulin-based antidiabetic (NIAD) combined with metformin. After propensity score matching, 11,746 patients were obtained, 5873 in each group.
RESULTS
The most used molecules as SGLT2i were dapagliflozin (51.3%) and empagliflozin (34.9%). The prevalence of CV risk factors was dyslipidemia (63.8%) and hypertension (62.9%), and CV disease was present in 7.7% of the patients. CKD prevalence was 1.8%. Patients in the SGLT2i group was younger (53.9 [10.3] vs 60.6 [13.1], p<0.001) with had higher body mass index (32.6 [5.6] vs 31.6 [5.9]; p<0.001), HbA1c (p<0.001), better kidney function (p<0.001) and lower albuminuria (p<0.001). No differences were observed in the cholesterol levels (p=0.519).
CONCLUSIONS
The findings of the DIAB-CV-AP study will expand our knowledge of SGLT2 inhibitors in the early stages of type 2 diabetes mellitus. The recruited cohort, with a lower baseline cardiovascular risk profile than other clinical trials and real-life studies, provides a solid basis for future analyses that will assess whether the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 52,739 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.